Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
41

Recommended

Shares screen as undervalued after prolonged decline.

Roy Van Keulen | 09 February 2026

With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.

Mark Giarelli | 09 February 2026

Our view after merger talks end.

Jon Mills, CFA | 09 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,175.90	1.50	0.02%
CAC 40	8,323.28	49.44	0.60%
DAX 40	25,014.87	293.41	1.19%
Dow JONES (US)	50,135.87	20.20	0.04%
FTSE 100	10,386.23	16.48	0.16%
HKSE	27,027.16	467.21	1.76%
NASDAQ	23,238.67	207.46	0.90%
Nikkei 225	56,363.94	2,110.26	3.89%
NZX 50 Index	13,486.08	39.71	0.30%
S&P 500	6,964.82	32.52	0.47%
S&P/ASX 200	8,913.60	2.00	0.02%
SSE Composite Index	4,123.09	57.51	1.41%